1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Market Overview
3.2. Introduction
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Ceftriaxone Market Forecast
4.5. Global Ceftriaxone Market Outlook
5. Market Outlook
5.1. Key Market Trends
5.2. Regulatory Scenario, by Region
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ceftriaxone Market Analysis and Forecast, by Indication
6.1. Introduction
6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
6.3. Global Ceftriaxone Market Forecast, by Indication
6.3.1. Urinary Tract Infections
6.3.2. Intra-abdominal Infections
6.3.3. Endocarditis
6.3.4. Acute Bacterial Otitis Media
6.3.5. Meningitis
6.3.6. Pneumonia
6.3.7. Others
7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel
7.1. Introduction
7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Ceftriaxone Market Analysis, by Distribution Channel
8. Global Ceftriaxone Market Analysis, by Region
8.1. Global Ceftriaxone Market Analysis, by Region
8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
8.3. Global Ceftriaxone Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America Ceftriaxone Market Analysis
9.1. North America Ceftriaxone Market Overview
9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
9.3. North America Ceftriaxone Market Forecast, by Country
9.3.1. U.S.
9.3.2. Canada
9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
9.5. North America Ceftriaxone Market Forecast, by Indication
9.5.1. Urinary Tract Infections
9.5.2. Intra-abdominal Infections
9.5.3. Endocarditis
9.5.4. Acute Bacterial Otitis Media
9.5.5. Meningitis
9.5.6. Pneumonia
9.5.7. Others
9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
10. Europe Ceftriaxone Market Analysis
10.1. Europe Ceftriaxone Market Overview
10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
10.5. Europe Ceftriaxone Market Forecast, by Indication
10.5.1. Urinary Tract Infections
10.5.2. Intra-abdominal Infections
10.5.3. Endocarditis
10.5.4. Acute Bacterial Otitis Media
10.5.5. Meningitis
10.5.6. Pneumonia
10.5.7. Others
10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
11. Asia Pacific Ceftriaxone Market Analysis
11.1. Asia Pacific Ceftriaxone Market Overview
11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia & New Zealand
11.3.5. Rest of Asia Pacific
11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
11.5.1. Urinary Tract Infections
11.5.2. Intra-abdominal Infections
11.5.3. Endocarditis
11.5.4. Acute Bacterial Otitis Media
11.5.5. Meningitis
11.5.6. Pneumonia
11.5.7. Others
11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
12. Latin America Ceftriaxone Market Analysis
12.1. Latin America Ceftriaxone Market Overview
12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
12.5. Latin America Ceftriaxone Market Forecast, by Indication
12.5.1. Urinary Tract Infections
12.5.2. Intra-abdominal Infections
12.5.3. Endocarditis
12.5.4. Acute Bacterial Otitis Media
12.5.5. Meningitis
12.5.6. Pneumonia
12.5.7. Others
12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
13. Middle East & Africa Ceftriaxone Market Analysis
13.1. Middle East & Africa Ceftriaxone Market Overview
13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of Middle East & Africa
13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
13.5.1. Urinary Tract Infections
13.5.2. Intra-abdominal Infections
13.5.3. Endocarditis
13.5.4. Acute Bacterial Otitis Media
13.5.5. Meningitis
13.5.6. Pneumonia
13.5.7. Others
13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
14. Competitive Analysis
14.1. Competition Matrix
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profile
14.3.1. Hikma Pharmaceuticals plc
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Qilu Pharmaceutical Co. Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. Baxter International, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Aurobindo Pharma
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Strategic Overview
14.3.5.4. SWOT Analysis
14.3.6. ACS DOBFAR S.P.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Strategic Overview
14.3.6.4. SWOT Analysis
14.3.7. Orchid Pharma
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Strategic Overview
14.3.7.4. SWOT Analysis
14.3.8. Nectar Lifesciences Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Lupin Pharmaceuticals, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis
世界のセフトリアキソン市場2022-2031：疾患別（尿路感染症、腹腔内感染症、心内膜炎、急性細菌性中耳炎、髄膜炎、肺炎、その他） |
| 【英語タイトル】Ceftriaxone Market (Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 | |
 | ・商品コード：TMR23FB038 ・発行会社（調査会社）：Transparency Market Research ・発行日：2022年12月14日 ・ページ数：170 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内） ・調査対象地域：グローバル ・産業分野：医薬品 |
| Single User（1名様閲覧） | USD5,795 ⇒換算￥880,840 | 見積依頼/購入/質問フォーム |
| Multi User（5名様閲覧） | USD8,795 ⇒換算￥1,336,840 | 見積依頼/購入/質問フォーム |
| Corporate License（法人閲覧） | USD11,795 ⇒換算￥1,792,840 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| Transparency Market Research社の市場調査では、2022年に17億ドルであった世界のセフトリアキソン市場規模が2031年には22億ドルまで達し、予測期間中に年平均2.9％成長すると予測しています。当書では、セフトリアキソンの世界市場について広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場動向、市場展望、疾患別（尿路感染症、腹腔内感染症、心内膜炎、急性細菌性中耳炎、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競合分析などの項目を掲載しています。また、当書には、Hikma Pharmaceuticals plc、Qilu Pharmaceutical Co. Ltd.、Novartis AG、Baxter International, Inc.、Aurobindo Pharma、ACS DOBFAR S.P.A.、Orchid Pharma、Nectar Lifesciences Ltd.、Lupin Pharmaceuticals, Inc.などの企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場動向 ・市場展望 ・世界のセフトリアキソン市場規模：疾患別 - 尿路感染症における市場規模 - 腹腔内感染症における市場規模 - 心内膜炎における市場規模 - 急性細菌性中耳炎における市場規模 - その他疾患における市場規模 ・世界のセフトリアキソン市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界のセフトリアキソン市場規模：地域別 - 北米のセフトリアキソン市場規模 - ヨーロッパのセフトリアキソン市場規模 - アジア太平洋のセフトリアキソン市場規模 - 中南米のセフトリアキソン市場規模 - 中東・アフリカのセフトリアキソン市場規模 ・競合分析 |
Ceftriaxone Market – Scope of Report
TMR’s report on the global ceftriaxone market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ceftriaxone market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ceftriaxone market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ceftriaxone market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ceftriaxone market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ceftriaxone market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ceftriaxone market.
The report delves into the competitive landscape of the global ceftriaxone market. Key players operating in the global ceftriaxone market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ceftriaxone market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ceftriaxone.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
❖ レポートの目次 ❖
| ★調査レポート[世界のセフトリアキソン市場2022-2031：疾患別（尿路感染症、腹腔内感染症、心内膜炎、急性細菌性中耳炎、髄膜炎、肺炎、その他）] (コード：TMR23FB038)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界のセフトリアキソン市場2022-2031：疾患別（尿路感染症、腹腔内感染症、心内膜炎、急性細菌性中耳炎、髄膜炎、肺炎、その他）]についてメールでお問い合わせ |
